INTEGRA LIFESCIENCES HOLDINGS CORP (IART) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.36%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.36% | Share-based compensation / revenue. Period ending 2026-06-30. $22.43M ÷ $1.65B × 100 ≈ 1.36% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 1.65B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 22.43M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 65.56M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.65B | $22.43M | $65.56M | (m) | (m) | 1.36% | (m) | (m) |
| 2026-03-31 | (m) | $1.64B | $21.88M | $-466.40M | (m) | (m) | 1.33% | (m) | (m) |
| 2025-12-31 | (m) | $1.64B | $18.58M | $-493.37M | (m) | (m) | 1.14% | (m) | (m) |
| 2025-09-30 | (m) | $1.64B | $19.90M | $-480.78M | (m) | (m) | 1.21% | (m) | (m) |
| 2025-06-30 | (m) | $1.62B | $18.70M | $-500.69M | (m) | (m) | 1.15% | (m) | (m) |
| 2025-03-31 | (m) | $1.62B | $20.65M | $8.95M | (m) | (m) | 1.27% | (m) | (m) |
| 2024-12-31 | (m) | $1.61B | $24.38M | $28.41M | (m) | (m) | 1.51% | (m) | (m) |
| 2024-09-30 | (m) | $1.56B | $23.02M | $28.83M | (m) | (m) | 1.47% | (m) | (m) |
| 2024-06-30 | (m) | $1.57B | $24.09M | $63.58M | (m) | (m) | 1.54% | (m) | (m) |
| 2024-03-31 | (m) | $1.53B | $22.12M | $79.11M | $52.90M | (m) | 1.45% | 1.50× | Reported |
| 2023-12-31 | (m) | $1.54B | $20.14M | $111.53M | $51.38M | (m) | 1.31% | 2.17× | Reported |
| 2023-09-30 | (m) | $1.54B | $20.08M | $143.32M | $50.52M | (m) | 1.30% | 2.84× | Reported |
| 2023-06-30 | (m) | $1.55B | $23.59M | $181.78M | $50.27M | (m) | 1.53% | 3.62× | Reported |
| 2023-03-31 | (m) | $1.56B | $25.05M | $229.14M | $50.04M | (m) | 1.60% | 4.58× | Reported |
| 2022-12-31 | (m) | $1.56B | $27.73M | $238.92M | $49.59M | (m) | 1.78% | 4.82× | Reported |
| 2022-09-30 | (m) | $1.57B | $28.43M | $229.30M | $48.83M | (m) | 1.82% | 4.70× | Reported |
| 2022-06-30 | (m) | $1.57B | $27.20M | $220.69M | $48.21M | (m) | 1.74% | 4.58× | Reported |
| 2022-03-31 | (m) | $1.56B | $36.17M | $212.68M | $49.12M | (m) | 2.32% | 4.33× | Reported |
| 2021-12-31 | (m) | $1.54B | $36.21M | $197.23M | $50.40M | (m) | 2.35% | 3.91× | Reported |
| 2021-09-30 | (m) | $1.53B | $35.03M | $191.65M | $55.62M | (m) | 2.30% | 3.45× | Reported |
| 2021-06-30 | (m) | $1.51B | $32.70M | $192.75M | $64.22M | (m) | 2.17% | 3.00× | Reported |
| 2021-03-31 | (m) | $1.38B | $22.17M | $154.98M | $66.76M | (m) | 1.61% | 2.32× | Reported |
| 2020-12-31 | (m) | $1.37B | $19.59M | $151.37M | $71.58M | (m) | 1.43% | 2.11× | Reported |
| 2020-09-30 | (m) | $1.38B | $19.84M | $134.81M | $67.69M | (m) | 1.44% | 1.99× | Reported |
| 2020-06-30 | (m) | $1.39B | $20.32M | $56.68M | $60.86M | (m) | 1.46% | 0.93× | Reported |
| 2020-03-31 | (m) | $1.51B | $20.92M | $88.56M | $58.56M | (m) | 1.38% | 1.51× | Reported |
| 2019-12-31 | (m) | $1.52B | $21.25M | $93.76M | $53.96M | (m) | 1.40% | 1.74× | Reported |
| 2019-09-30 | $73.58M | $1.51B | $20.74M | $91.79M | $54.43M | 4.89% | 1.38% | 1.69× | Reported |
| 2019-06-30 | $76.56M | $1.49B | $20.42M | $136.05M | $54.94M | 5.13% | 1.37% | 2.48× | Reported |
| 2019-03-31 | $78.04M | $1.48B | $20.13M | $117.73M | $59.06M | 5.29% | 1.36% | 1.99× | Reported |
| 2018-12-31 | $78.04M | $1.47B | $20.78M | $111.00M | $64.68M | 5.30% | 1.41% | 1.72× | Reported |
| 2018-09-30 | $74.92M | (m) | $20.98M | $84.11M | $67.70M | (m) | (m) | 1.24× | Reported |
| 2018-06-30 | $69.65M | (m) | $20.71M | $71.07M | $59.98M | (m) | (m) | 1.18× | Reported |
| 2018-03-31 | $66.29M | (m) | $20.92M | $60.42M | $48.66M | (m) | (m) | 1.24× | Reported |
| 2017-12-31 | $63.45M | (m) | $21.55M | $44.80M | $35.02M | (m) | (m) | 1.28× | Reported |
| 2017-09-30 | $60.18M | (m) | $20.90M | $78.36M | $24.62M | (m) | (m) | 3.18× | Reported |
| 2017-06-30 | $60.27M | (m) | $20.46M | $97.81M | $24.15M | (m) | (m) | 4.05× | Reported |
| 2017-03-31 | $59.20M | (m) | $19.41M | $103.20M | $24.56M | (m) | (m) | 4.20× | Reported |
| 2016-12-31 | $58.16M | (m) | $17.31M | $115.34M | $25.80M | (m) | (m) | 4.47× | Reported |
| 2016-09-30 | $58.12M | (m) | $16.43M | $98.58M | $25.35M | (m) | (m) | 3.89× | Reported |
| 2016-06-30 | $56.93M | (m) | $17.93M | $78.48M | $25.52M | (m) | (m) | 3.08× | Reported |
| 2016-03-31 | $54.27M | (m) | $16.41M | $80.47M | $24.42M | (m) | (m) | 3.30× | Reported |
| 2015-12-31 | $50.90M | (m) | $15.45M | $79.59M | $23.52M | (m) | (m) | 3.38× | Reported |
| 2015-09-30 | $55.08M | (m) | $15.66M | $82.84M | $22.93M | (m) | (m) | 3.61× | Reported |
| 2015-06-30 | $51.73M | (m) | $12.42M | $75.15M | $22.41M | (m) | (m) | 3.35× | Reported |
| 2015-03-31 | $51.59M | (m) | $15.01M | $73.59M | $22.32M | (m) | (m) | 3.30× | Reported |
| 2014-12-31 | $51.60M | (m) | $15.11M | $65.54M | $21.97M | (m) | (m) | 2.98× | Reported |
| 2014-09-30 | $53.95M | (m) | $14.49M | $56.48M | $21.15M | (m) | (m) | 2.67× | Reported |
| 2014-06-30 | $53.88M | (m) | $13.93M | $7.61M | $20.55M | (m) | (m) | 0.37× | Reported |
| 2014-03-31 | $51.94M | (m) | $10.79M | $7.28M | $20.13M | (m) | (m) | 0.36× | Reported |
| 2013-12-31 | $52.09M | (m) | $10.39M | $-3.64M | $19.79M | (m) | (m) | -0.18× | Reported |
| 2013-09-30 | $50.44M | (m) | $10.01M | $-3.12M | $16.74M | (m) | (m) | -0.19× | Reported |
| 2013-06-30 | $50.49M | (m) | $9.46M | $46.23M | $16.97M | (m) | (m) | 2.72× | Reported |
| 2013-03-31 | $51.82M | (m) | $9.05M | $56.27M | $19.11M | (m) | (m) | 2.94× | Reported |
| 2012-12-31 | $51.01M | (m) | $9.05M | $73.78M | $22.24M | (m) | (m) | 3.32× | Reported |
| 2012-09-30 | $51.55M | (m) | $14.54M | $62.97M | $28.44M | (m) | (m) | 2.21× | Reported |
| 2012-06-30 | $51.63M | (m) | $15.30M | $61.53M | $30.48M | (m) | (m) | 2.02× | Reported |
| 2012-03-31 | $51.21M | (m) | $24.84M | $51.51M | $30.10M | (m) | (m) | 1.71× | Reported |
| 2011-12-31 | $51.45M | (m) | $26.80M | $54.91M | $27.64M | (m) | (m) | 1.99× | Reported |
| 2011-09-30 | $51.38M | (m) | $24.65M | $71.33M | $24.90M | (m) | (m) | 2.86× | Reported |
| 2011-06-30 | $49.91M | (m) | $25.55M | $80.34M | $21.71M | (m) | (m) | 3.70× | Reported |
| 2011-03-31 | $48.97M | (m) | $17.40M | $96.92M | $19.28M | (m) | (m) | 5.03× | Reported |
| 2010-12-31 | $48.11M | (m) | $17.21M | $98.69M | $18.36M | (m) | (m) | 5.38× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $44.28M | (m) | $15.58M | $97.82M | $23.23M | (m) | (m) | 4.21× | Reported |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $60.49M | (m) | $32.63M | $47.41M | $30.09M | (m) | (m) | 1.58× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |